cagrisema phase 3 results 2025 semaglutide cagrilintide obesity In the REDEFINE 2 3a trial involving adults with and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial Novo Nordisk presents new Phase

Understanding these distinctions helps determine which approach aligns with your weight management goals

For many patients, this is fine

Improves blood sugar control Semaglutide not only helps with weight loss, but also significantly improves blood sugar levels by enhancing insulin secretion and reducing glycogenesis in the liver

Subsequently, attention turned to other glucose-lowering agents, including GLP-1 receptor agonists

While compounded semaglutide carries additional risks compared to FDA-approved versions, it does offer certain advantages for specific patient populations

PlexusDx uses genetic testing as an optional add-on ($99 after your first month of treatment) to help tailor dosing strategies and identify which patients need long-term continuous coverage versus occasional maintenance approaches